New drug shows promise in reducing COPD symptoms in former and current smokers, clinical trials show

Live updates

1. 6d ago

   AstraZeneca's Tozorakimab Reduces COPD Exacerbations in Phase III Trials

   AstraZeneca's investigational biologic therapy, tozorakimab, significantly reduced moderate and severe COPD exacerbations in two late-stage clinical trials named OBERON and TITANIA. The drug showed benefits across various patient groups, including current and former smokers who continued to experience flare-ups despite receiving standard inhaled care. Data presented at ERS 2026 indicate the IL-33 antibody provides a clinically meaningful reduction in exacerbations when added to standard treatment. AstraZeneca R&D chief Barr described the results as an internal science success story, boosting hopes that the drug will become a blockbuster treatment.

   Why it matters

   Chronic obstructive pulmonary disease often requires inhaled standard-of-care therapy, but many patients still suffer from frequent flare-ups. Biologic therapies target specific inflammatory pathways to prevent these exacerbations. This development focuses on the IL-33 antibody pathway to improve outcomes for high-risk patients.

   What is confirmed

   • Tozorakimab demonstrated a statistically significant and clinically meaningful reduction in COPD exacerbations in the OBERON and TITANIA Phase III trials.
   • The drug reduced flare-ups in patients who continued to experience exacerbations despite using standard inhaled therapy.
   • Tozorakimab is an IL-33 antibody biologic therapy.
   • The therapy showed benefits across patient groups, including former and current smokers.

   Still unconfirmed

   • Semaglutide is associated with fewer asthma attacks and COPD exacerbations.

   What to watch next

   • Publication of full peer-reviewed data from the OBERON and TITANIA trials.
   Sources used for this update (10)

   1. www.today.com — Is There a Summer COVID Surge? With Cases Rising in Nearly Every State, Watch for These Symptoms
   2. CNBC — AstraZeneca's COPD drug scores two late-stage trial wins as full data boosts blockbuster hopes
   3. ABC News - Breaking News, Latest News and Videos — New drug shows promise in reducing COPD symptoms in former and current smokers, clinical trials show
   4. WSJ — AstraZeneca Says Lung-Disease Drug Shows Benefits Across Patient Groups
   5. AstraZeneca — Tozorakimab demonstrated statistically significant and highly clinically meaningful reduction in COPD exacerbations in OBERON and TITANIA Phase III trials
   6. Fierce Biotech — AZ's R&D chief Barr touts internal 'science success story' after IL-33 antibody's stellar showing in COPD
   7. Endpoints News — Sanofi spells out asthma data, AstraZeneca details COPD win at #ERS26
   8. www.news-medical.net — New biologic therapy significantly reduces COPD flare-ups in trials
   9. finance.yahoo.com — ERS 2026: tozorakimab’s groundbreaking exacerbation reduction sets a new bar in COPD
   10. respiratory-therapy.com — Semaglutide Tied to Fewer Asthma, COPD Exacerbations
   confidence 100%